Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study
Context: We previously designed, developed and characterized a novel microencapsulated formulation as a platform for the targeted delivery of Probucol (PB) in an animal model of Type 2 Diabetes. Objective: The objective of this study is to optimize this platform by incorporating Chenodeoxycholic aci...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Taylor and Francis Ltd
2015
|
| Online Access: | http://hdl.handle.net/20.500.11937/44153 |
| _version_ | 1848756915596689408 |
|---|---|
| author | Mooranian, A. Negrulj, R. Mikov, M. Golocorbin-Kon, S. Arfuso, Frank Al-Salami, Hani |
| author_facet | Mooranian, A. Negrulj, R. Mikov, M. Golocorbin-Kon, S. Arfuso, Frank Al-Salami, Hani |
| author_sort | Mooranian, A. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Context: We previously designed, developed and characterized a novel microencapsulated formulation as a platform for the targeted delivery of Probucol (PB) in an animal model of Type 2 Diabetes. Objective: The objective of this study is to optimize this platform by incorporating Chenodeoxycholic acid (CDCA), a bile acid with good permeation-enhancing properties, and examine its effect in vitro. Using sodium alginate (SA), we prepared PB-SA (control) and PB-CDCA-SA (test) microcapsules. Results and discussion: CDCA resulted in better structural and surface characteristics, uniform morphology, and stable chemical and thermal profiles, while size and rheological parameters remained unchanged. PB-CDCA-SA microcapsules showed good excipients compatibilities, as evidenced by differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy, scanning electron microscopy and energy dispersive X-ray spectroscopy studies. CDCA reduced microcapsule swelling at pH 7.8 at both 37 °C and 25 °C and improved PB-release. Conclusion: CDCA improved the characteristics and release properties of PB-microcapsules and may have potential in the targeted oral delivery of PB. |
| first_indexed | 2025-11-14T09:19:47Z |
| format | Journal Article |
| id | curtin-20.500.11937-44153 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T09:19:47Z |
| publishDate | 2015 |
| publisher | Taylor and Francis Ltd |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-441532017-09-13T14:28:47Z Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study Mooranian, A. Negrulj, R. Mikov, M. Golocorbin-Kon, S. Arfuso, Frank Al-Salami, Hani Context: We previously designed, developed and characterized a novel microencapsulated formulation as a platform for the targeted delivery of Probucol (PB) in an animal model of Type 2 Diabetes. Objective: The objective of this study is to optimize this platform by incorporating Chenodeoxycholic acid (CDCA), a bile acid with good permeation-enhancing properties, and examine its effect in vitro. Using sodium alginate (SA), we prepared PB-SA (control) and PB-CDCA-SA (test) microcapsules. Results and discussion: CDCA resulted in better structural and surface characteristics, uniform morphology, and stable chemical and thermal profiles, while size and rheological parameters remained unchanged. PB-CDCA-SA microcapsules showed good excipients compatibilities, as evidenced by differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy, scanning electron microscopy and energy dispersive X-ray spectroscopy studies. CDCA reduced microcapsule swelling at pH 7.8 at both 37 °C and 25 °C and improved PB-release. Conclusion: CDCA improved the characteristics and release properties of PB-microcapsules and may have potential in the targeted oral delivery of PB. 2015 Journal Article http://hdl.handle.net/20.500.11937/44153 10.3109/02652048.2015.1065922 Taylor and Francis Ltd restricted |
| spellingShingle | Mooranian, A. Negrulj, R. Mikov, M. Golocorbin-Kon, S. Arfuso, Frank Al-Salami, Hani Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study |
| title | Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study |
| title_full | Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study |
| title_fullStr | Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study |
| title_full_unstemmed | Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study |
| title_short | Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study |
| title_sort | novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. an in vitro study |
| url | http://hdl.handle.net/20.500.11937/44153 |